Drug Safety: More sensitive sensor developed
Image of cells expressing the AgHalo sensor before (left) and after (right) cellular stress. The AgHalo sensor is turned on when misfolded proteins begin to aggregate and provides a quantitative measure of cellular stress that can be used to evaluate drug safety. Credit: Yu Liu, Penn State University
A new technique for evaluating drug safety can detect stress on cells at earlier stages than conventional methods, which mostly rely on detecting cell death. according to researchers at Penn State.
The new method uses a fluorescent sensor that is turned on in a cell when misfolded proteins begin to aggregate — an early sign of cellular stress. The method can be adapted to detect protein aggregates caused by other toxins as well as diseases such as Alzheimer’s or Parkinson’s.
A paper describing the new method appears in the journal Angewandte Chemie International Edition.
“Drug-induced protein stress in cells is a key factor in determining drug safety,” said Xin Zhang, assistant professor of chemistry and of biochemistry and molecular biology at Penn State, the senior author of the paper. “Drugs can cause proteins — which are long strings of amino acids that need to be precisely folded to function properly — to misfold and clump together into aggregates that can eventually kill the cell. We set out to develop a system that can detect these aggregates at very early stages and that also uses technology that is affordable and accessible to many laboratories.”
The new system is the first to use a fluorescent sensor that is not turned on until the misfolded proteins begin to aggregate. The researchers designed an unstable protein — called AgHalo — that is tagged with a special fluorescent dye that becomes active in a hydrophobic, i.e. water-repellent, environment. Hydrophobic portions of proteins are usually buried deep in the structure of a properly-folded protein because the environment of the cell is mostly water. When the AgHalo protein begins to misfold and aggregate, the dye can interact with the hydrophobic portions of the protein and begin to fluoresce.
Previous systems used sensors that were always on. The cells would have a general diffuse fluorescence prior to any stress and the systems could only detect protein stress when the misfolded proteins aggregated, forming brighter spots of fluorescence that were large enough to be seen under a microscope.
“An additional advantage of our system is that the level of fluorescence is correlated to the amount of protein aggregation in the cell, so we can quantify the level of stress,” said Yu Liu, a postdoctoral researcher at Penn State and the first author of the paper. “Also, because our method measures the level of fluorescence, rather than having to identify the fluorescence under a microscope, it can be done using more accessible technology, like plate readers, and it is much more high-throughput.”
The researchers used their sensor to test the level of protein stress caused by five commonly-used, anti-cancer drugs. Although none of the drugs they tested caused significant cell death in previous drug safety tests, all five produced some level of protein stress detectable by the AgHalo sensor.
“Because we tested the anti-cancer drugs at much higher doses than typically used for treatment, our results do not necessarily call into question the continued use of these drugs,” said Liu. “However, because protein stress from long-term treatments could have lasting effects, evaluating drugs with our new sensor will help in the development of safer drugs.”
Protein stress can be induced by other many factors. Heat, toxins, bacterial infections, cancer, and even aging can cause proteins to misfold and form aggregates in cells. “With our method, we can quantitatively detect protein stress in cells at much earlier stages and therefore researchers can begin to study the mechanisms that cells use to combat this stress and develop compounds that can enhance the cell’s ability to handle protein stress,” said Zhang.
This article has been republished from materials provided by Penn State University. Note: material may have been edited for length and content. For further information, please contact the cited source.
Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous SclerosisNews
Addressing a critical issue for people with a genetic disorder called tuberous sclerosis complex (TSC), doctors reported that a skin cream containing rapamycin significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with the condition.READ MORE
Calidi Biotherapeutics, Inc. Announces its Corporate Vision in Groundbreaking Cancer Drug DevelopmentNews
Calidi Biotherapeutics, Inc., formerly StemImmune, Inc., a clinical‐stage biotherapeutics company at the forefront of oncolytic virus-based immunotherapies for cancer, announced a focused effort to advance its oncolytic virus drug development.READ MORE
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE